Survodutide Impresses in Phase 2 Weight-Loss Trial ...Middle East

Medscape - News
This dual GLP-1 and glucagon receptor agonist resulted in 'striking' weight loss in a phase 2 dosing trial of people with overweight/ obesity but without type 2 diabetes. Medscape Medical News

Hence then, the article about survodutide impresses in phase 2 weight loss trial was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Survodutide Impresses in Phase 2 Weight-Loss Trial )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News